Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
It is interesting to note that the threat actually comes from WH Ireland.
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
· OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
· Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
· IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.
· Multibillion-dollar DED market whose medical needs remain largely unmet.
· AmbioPharm supporting OK-101 program with peptide synthesis and development.
so welcome!
You are missing the point. The scale of this opportunity is huge.
This RNS indicates a transformation in the prospects for Verditek, a unique and ideal application of their technology with a leading and very large European distributor with a turnover in 2019 that was 1,8 billion Norwegian kroner. That's just shy of £150 million pounds.
These price movements smack of manipulation IMO. Nothing more, nothing less.
Much more significant than the Sunday Times is the long article about Cobalt in Vanity Fair: https://t.co/tsCRqO0093 as as Tweeted by BlueJay. I will be very surprised if this does not garner considerable attention on BlueJay among the investment community Stateside. Furthermore it becomes abundantly clear that no drilling is no impediment as the technology that will be used this year to identify what Disko has is way more advanced than anything which has yet ever been used in the mining industry. You don have all those PhDs and Gates and Bezos on your side for nothing. Well done Rod and all.
About Daewoong Pharmaceutical. Co., Ltd.
(https://www.daewoong.co.kr/en)
Current Market Capitalisation: $182,100,000,000,000
Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets. With a strong and innovative in-house R&D and advanced manufacturing facilities, Daewoong provides a total healthcare solution to customers across the globe. Continuing on their course of building a strong global healthcare company, Daewoong has broadened international operations by establishing branch offices and research centers throughout Asia and the United States. Daewoong has also expanded strategic partnerships in more than 100 countries worldwide.
https://www.nasdaq.com/articles/metaverse-etfs-set-for-exponential-growth
https://youtu.be/1k9r4wEvH2A
BR Business News: Bo Møller Stensgaard, CEO, discusses the exploration & drilling programme at Disko, a game-changing asset hosting an abundance of metals critical to the #greenrevolution, & where KoBold’s cutting-edge technology will collect high-quality data from Q2 2022